Form 4: Eagle Pharmaceuticals Director Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Scott Tarriff, a director at Eagle Pharmaceuticals, sold shares to cover tax obligations related to vesting restricted stock units.
Summary
- On February 28, 2024, Scott Tarriff, a director at Eagle Pharmaceuticals, sold 2,119 shares of common stock to cover tax obligations.
- The sale price was $6.27 per share.
- Following the transaction, Tarriff directly owns 460,621 shares and indirectly owns 992,623 shares through the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016.
- Tarriff disclaims beneficial ownership of the shares held by the trust, except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: This is a neutral transaction related to tax obligations. It doesn't indicate a positive or negative outlook for the company.
Industry Context
This is a routine Form 4 filing related to insider transactions. It is common for company directors and officers to sell shares to cover tax obligations when restricted stock units vest.
Key Dates
| Date | Description |
|---|---|
| 12/28/2016 | Date of the Tarriff 2016 Generation Skipping Exempt Family Trust DTD |
| 02/28/2024 | Date of the transaction (share sale) |
| 03/01/2024 | Date of signature on the Form 4 filing |
Keywords
Eagle Pharmaceuticals, Scott Tarriff, Form 4, Share Sale, Director, Tax Obligations, EGRX, Beneficial Ownership, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.